Maryland Endocrine Partners With eClinicalWorks and healow Genie to Transform Patient Experiences With AI-Powered Contact Center Solution
WESTBOROUGH, Mass.--(BUSINESS WIRE)-- eClinicalWorks®, the largest ambulatory cloud EHR, today announced the integration of healow® Genie, an AI-powered contact center solution, across Maryland Endocrine practices. This innovative partnership will offer patients round-the-clock access to crucial health information through text, chatbots, and voice calls. Created to manage a wide array of tasks, including scheduling appointments, facilitating bill payments, and supervising medication refills or referral requests, healow Genie is set to significantly transform operations at Maryland Endocrine.
"We're thrilled to harness the capabilities of healow Genie to efficiently manage our high call volume, optimize operational workflows, and provide swift and personalized assistance," said Kimberly Stahl, practice administrator at Maryland Endocrine. "healow Genie's multilingual capability will help us overcome language barriers. Its personable demeanor, and its role in reducing patient wait times will streamline our day-to-day operations. Currently, we rely on a third-party service for after-hours calls, which is costly and inefficient. With the implementation of healow Genie, we expect patient engagement and satisfaction to be elevated and costs to be reduced by automating critical functions such as appointment scheduling, prescription management, and referral handling."
Serving the Central Maryland community, Maryland Endocrine specializes in various endocrine services. The practice has emerged as a trusted provider for many seeking timely evaluations and treatments for conditions including pituitary disease, thyroid disease, Diabetes Mellitus, bone, calcium, and parathyroid disorders.
'We are incredibly excited to partner with Maryland Endocrine with the integration of healow Genie to strengthen patient engagement at its facilities,' said Girish Navani, CEO and co-founder of eClinicalWorks. "Our objective is to usher in a paradigm shift in healthcare practices facing challenges with call center operations. The integration of healow Genie, an AI-powered tool, optimizes operations and boosts patient satisfaction with its efficient and intelligent capabilities."
healow Genie is crafted to redefine patient communication, augment the accessibility of healthcare information and resources, and simplify appointment management. With remarkable features such as patient self-service, intelligent assistance, automated service for after-hours, and engaging brilliant campaigns, healow Genie stands ready to dramatically enhance the healthcare journey for patients at Maryland Endocrine. For more information about healow Genie and its capabilities, visit genie.healow.com.
About Maryland Endocrine
Maryland Endocrine is a trusted healthcare provider specializing in various endocrine services in Central Maryland. With years of dedicated service, the practice has become a leading choice for many seeking comprehensive evaluations and treatments for a wide array of conditions, including but not limited to pituitary disease, thyroid disease, diabetes, bone, calcium, and parathyroid disorders, adrenal disease, and reproductive diseases. It also guides patients toward suitable healthcare providers for challenges outside their purview. Maryland Endocrine is deeply committed to delivering accessible, efficient, and top-tier healthcare services to its community. For more information, visit marylandendocrine.com.
About eClinicalWorks
eClinicalWorks was founded in 1999 to help digitize paper charts for ambulatory practices. Today, eClinicalWorks innovates the nation with cloud-based Electronic Health Records and Practice Management solutions. In addition, we help ambulatory practices, specialists, health centers, urgent care facilities, and hospital systems manage their revenue cycle, patient relationships, and Population Health initiatives. More than 180,000 providers and 1 million medical professionals rely upon the power and scalability of the eCW Cloud for flexible clinical documentation, better front-office workflows, and more efficient billing driven by Robotic Process Automation. We combine innovation, leading-edge technology, and a commitment to patient safety to enable practices to grow and thrive amid the challenges of 21st-century healthcare. For more information, visit www.eclinicalworks.com, follow us on LinkedIn, Facebook and X/Twitter, or call (866) 888-6929.
About healow Genie
healow® Genie is a first-of-its-kind, EHR-agnostic, AI-powered contact center solution designed to enhance patient engagement by providing patients 24/7 access to vital health information via voice call, text, or chatbot. It offers a comprehensive suite of features, including patient self-service, intelligent assistant, automated after-hours service, and conversational smart campaigns. Genie improves patient satisfaction, reduces administrative burden on staff, and lowers overall operational costs. For more information, visit https://genie.healow.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
